SCHEMBL2942575

SCHEMBL2942575

Fc1ccc(-c2cnc3ccc(NCCc4cccnc4)nn23)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.66
MKNK1 Q9BUB5 6/20 0.64
PIK3CD O00329 1/20 0.64
PIK3R1 P27986 1/20 0.64
FYN P06241 9/20 0.62
NTRK1 P04629 4/20 0.54
NTRK3 Q16288 4/20 0.54
NTRK2 Q16620 4/20 0.54
JAK2 O60674 1/20 0.49
ABL1 P00519 1/20 0.49
INSR P06213 1/20 0.49
LCK P06239 1/20 0.49
CSF1R P07333 1/20 0.49
LYN P07948 1/20 0.49
RET P07949 1/20 0.49
IGF1R P08069 1/20 0.49
MET P08581 1/20 0.49
ROS1 P08922 1/20 0.49
PDGFRB P09619 1/20 0.49
FGR P09769 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2943040 0.90 PIK3CD (0.70) PIM1MKNK1PIK3CDPIK3R1FYN
SCHEMBL2951018 0.89 MKNK1 (0.67) PIM1MKNK1PIK3CDPIK3R1FYN
SCHEMBL13234372 0.89 PIM1 (0.74) PIM1MKNK1PIK3CDPIK3R1FYN
SCHEMBL2949545 0.87 NTRK1 (0.68) PIM1MKNK1PIK3CDPIK3R1FYN
SCHEMBL2944865 0.87 FYN (0.69) PIM1MKNK1PIK3CDPIK3R1FYN
SCHEMBL2949676 0.86 PIM1 (0.65) PIM1MKNK1PIK3CDPIK3R1FYN
SCHEMBL13223378 0.86 FYN (0.67) PIM1MKNK1FYNNTRK1NTRK3
SCHEMBL1054752 0.85 PIK3CD (0.72) PIM1MKNK1PIK3CDPIK3R1FYN
SCHEMBL2941594 0.84 FYN (0.66) PIM1MKNK1PIK3CDPIK3R1FYN
SCHEMBL16331205 0.83 PIK3CD (0.57) PIM1MKNK1PIK3CDPIK3R1FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-7750000-B2 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER SCHERING PHARMA AG (DE) 2010-07-06 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments BAYER INTELLECTUAL PROPERTY GMBH (DE) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093490-A1 Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments MAP4K2, MAP3K1, MAP3K2 PIM1 365/4885MKNK1 144/4885PIK3CD 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.